The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
IDO1 inhibition with a 1st-generation inhibitor has shown promising clinical benefit in melanoma patients, as well as exacerbated toxicity, when combined with ipilimumab. We have identified a novel class of IDO1 inhibitors (IDO1i), which surpass the potency, selectivity and pharmacokinetic parameters of 1st-generation IDO1i.IDO1 inhibition was assessed from kynurenine (kyn) levels produced by stimulated...